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Hu-antigen R (HuR) is an RNA-binding posttranscriptional regulator that belongs to the Hu/ELAV family. HuR
expression levels are modulated by a variety of proteins, microRNAs, chemical compounds, or the
microenvironment, and in turn, HuR affects mRNA stability and translation of various genes implicated in breast
cancer formation, progression, metastasis, and treatment. The aim of the present review is to critically summarize
the role of HuR in breast cancer development and its potential as a prognosticator and a therapeutic target. In this
aspect, all the existing English literature concerning HuR expression and function in breast cancer cell lines, in vivo
animal models, and clinical studies is critically presented and summarized. HuR modulates many genes implicated
in biological processes crucial for breast cancer formation, growth, and metastasis, whereas the link between HuR
and these processes has been demonstrated directly in vitro and in vivo. Additionally, clinical studies reveal that
HuR is associated with more aggressive forms of breast cancer and is a putative prognosticator for patients'
survival. All the above indicate HuR as a promising drug target for cancer therapy; nevertheless, additional studies
are required to fully understand its potential and determine against which types of breast cancer and at which
stage of the disease a therapeutic agent targeting HuR would be more effective.
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Hu-antigen R (HuR) or embryonic lethal, abnormal vision,
Drosophila (ELAV)–like protein 1 (ELAVL1) belongs to the Hu/
ELAV family and is a ubiquitously expressed RNA-binding
posttranscriptional regulator [1]. Early studies performed using the
neuronal-specific HuR ortholog HuB demonstrated that members of
the Hu/ELAV family contain three highly conserved RNA-binding
domains that belong to the RNA recognition motif (RRM)
superfamily [2]; RRM-1 and RRM-2 bind to AU-rich elements,
whereas RRM-3 binds to the poly(A) tail of rapidly degrading
mRNAs [3]. Similarly, a U-rich sequence approximately 17 to 20
nucleotides (nt) long, usually located within the 3′-untranslated
region (UTR) of the target mRNAs, has been identified as the RNA
motif recognized by HuR [4]. HuR binds to this motif and regulates
the stability, translation, and nucleocytoplasmic translocation of
target mRNAs. More specifically, HuR binding may stabilize themRNA, indirectly increasing protein production [5–8], whereas its
direct effect on translation efficiency can be either positive or negative
[9,10]. Moreover, mRNA exon-intron splicing and polyadenylation,
processes taking place in the nucleus, can also be modulated by HuR
[11–14]. Additionally, HuR can be transported from the nucleus,
where is most abundantly localized, to the cytoplasm, along with
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appears to be linked to regulating HuR function [16].
The regulatory mechanisms involved in HuR expression and
function have not been comprehensively studied. It appears that
phosphorylation plays an important role in its subcellular localization
and activity, and a number of kinases have been found to
phosphorylate HuR, including serine/threonine-protein kinase
Chk2 and protein kinase C delta (Table 1). Besides phosphorylation,
there is also evidence for HuR methylation [17]; however, the role of
this type of posttranslational modification is less well studied. HuR
mRNA and protein levels are altered in response to a number of
proteins and microRNAs such as miR-519 [18], hormones such as
17β-estradiol [19], cyclic GMP-elevating agents such as nitric oxide
[20], and drugs. Furthermore, HuR protein is degraded via the
ubiquitin-proteasome system [21] and undergoes caspase-mediated
cleavage during apoptosis [22].
Alterations in HuR expression levels or subcellular localization have
been associated with important medical conditions, such as
pathologic inflammation [23], atherosclerosis [24], tissue ischemia
[25], and, most significantly, tumor formation, growth, and
metastasis [26–29]. Furthermore, HuR appears to be responsible
for the expression regulation of mRNAs encoding proteins involved
in transcription, cell signaling, cell division cycle, apoptosis,
inflammation, and stress responses [5,10,30–33], many of them
cancer relevant and implicated in malignant transformation.
Moreover, clinical studies show that increased HuR expression levels
and cytoplasmic expression pattern correlate with malignant
phenotype and poor patient prognosis in various types of cancer [34].
Breast cancer is the most commonly reported malignancy and the
most common cause of cancer-related death among women.
Mammary tumors are highly complex and heterogeneous, and we
still lack a global understanding of the molecular mechanisms behind
breast cancer origin and progression [35]. Breast cancer cells are
classified as either positive or negative for the presence of each of three
important receptors: estrogen receptor-alpha (ER), tyrosine
kinase-type cell surface receptor HER2, and progesterone receptor.
Approximately 70% of breast tumors are ER positive and depend onTable 1. Regulation of HuR Localization and Activity via Phosphorylation
HuR Modification
Site
Kinase Effect on … Ref.
Ser88 Serine/threonine-protein kinase Chk2 target RNA stability
target RNA splicing
[14,39,40]
Ser100 Serine/threonine-protein kinase Chk2 target RNA stability
target RNA splicing
[14,39,40]
Thr118 Serine/threonine-protein kinase Chk2
Mitogen-activated protein kinase 14
HuR localization
target RNA stability
target RNA splicing
[14,39,41]
Ser158 Protein kinase C alpha HuR localization
target RNA stability
target RNA translation
[42,43]
Tyr200 Tyrosine-protein kinase JAK3 HuR localization
target RNA stability
[44]
Ser202 Cyclin-dependent kinase 1 HuR localization [45]
Ser221 Protein kinase C delta HuR localization
target RNA stability
target RNA translation
[43,46,47]
Ser318 Protein kinase C delta HuR localization
target RNA stability
target RNA translation
[46–48]estrogen for growth [36]. Therefore, ER-targeted endocrine therapies
are effective for the treatment of patients with ER-positive breast
tumors, and tamoxifen is the most widely used endocrine antiestrogen
treatment. Interestingly, a number of studies implicate HuR in ER
and HER2 expression regulation and tamoxifen resistance, suggesting
that HuR may play a crucial role in breast cancer development and
possibly treatment [37,38].
In the light of the above considerations, the aim of the current
review is to critically summarize the role of HuR in breast cancer as
illustrated by in vitro experiments, in vivo animal models, and clinical
studies and to examine its potential as a therapeutic target. Initially,
we present an overview of HuR expression and general function in
various breast cancer cell lines. Subsequently, we examined individual
gene products modulated by HuR either directly as demonstrated by
physical interaction between HuR and the target mRNA or in some
cases indirectly. Finally, we describe a number of HuR expression
regulators including microRNAs and commonly used therapeutic
drugs against breast cancer.
HuR Expression in Breast Cancer
HuR expression has been studied in a variety of breast-derived cell
lines exhibiting differential degrees of malignant potential. Both
MCF10A and MCF12A are nontumorigenic immortalized epithelial
cell lines and are considered to be normal breast cells. The MCF7 cell
line is epithelial adenocarcinoma, ER positive. The MDA-MB-231
cell line is also epithelial adenocarcinoma, ER negative, poorly
differentiated, and highly tumorigenic and invasive.
HuR expression has been reported in all the above cell lines, and
HuR mRNA levels in MDA-MB-231 cells are 2.5-fold higher than in
MCF7 cells and 5-fold higher than in MCF10A and MCF12A cells,
as shown by quantitative reverse transcriptase polymerase chain
reaction [49]. HuR mRNA was also found to be more stable in
MDA-MB-231 cells as compared with MCF10A cells, with its
half-life increasing from 1 hour in the latter to 4 hours in the former
[49]. Although HuR is mainly localized to the nucleus [50,51],
immunochemical studies revealed increased cytoplasmic HuR
expression in MDA-MB-231 in comparison with MCF7 cells [52],
as well as in MCF7 in comparison with MCF10A cells [53].
Interestingly, Hostetter et al. report that total HuR protein levels are
higher in MCF7 than in MDA-MB-231 cells [37], whereas Calaluce
et al. report similar HuR protein levels in MCF7 and MDA-MB-231
cells [52].
HuR expression has been also noted in nontumorigenic
immortalized epithelial HB2 [50] and HMT-3522-T4-2 [54] cells,
epithelial ductal carcinoma T47D [50,54–56] and ZR-75-1 cells
[57], epithelial carcinoma BT-20 [51] and Hs578T cells [58,59], and
epithelial adenocarcinoma SK-BR-3 cells [38,51,54,60,61].
A number of clinical studies revealed that HuR expression levels
were elevated in atypical ductal hyperplasia (ADH), ductal carcinoma
in situ (DCIS), and ductal invasive carcinoma (DIC) when compared
with healthy tissue samples [62–64]. Interestingly, cytoplasmic HuR
immunoreactivity was present in less than half of DIC [65–67],
DCIS, and ADH samples [64], as well as in invasive breast cancer
patients that underwent paclitaxel- and anthracycline-based neoad-
juvant chemotherapy (NACT) [68]. The cytoplasmic localization of
HuR in histological and cytological samples of invasive breast
carcinoma is evident in Figure 1.
Apart from the apparent association between increased HuR
mRNA levels and cytoplasmic HuR expression and a more malignant
Figure 1. Representative immunostainings for HuR protein
expression in histological and cytological samples of invasive
breast carcinoma (original magnification 400×).
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processes in different cell lines.
HuR knockdown in MCF10A cells revealed that HuR plays a
crucial role in cell proliferation as demonstrated by a colony
formation assay, reducing the number of colonies by up to 28%
and promoting premature senescence [69]. In another study,
siRNA-mediated HuR silencing decreased anchorage-independent
growth of malignant T-cell–amplified sequence 1 (MCT1)–trans-
formed MCF10A cells [70]. Additionally, HuR regulates cell polarity
and is responsible for the formation of the acinar structures of
MCF10A cells in 3D Matrigel culture [69]. Similarly, HuR
knockdown was found to significantly decrease growth of MCF7
but not MDA-MB-231 cells [57], whereas a second study confirmed
this observation, reporting a 35% reduction in MCF7 cell number
after siRNA-mediated HuR silencing [71]. However, in another
study, HuR overexpression in MDA-MB-231 cells was shown to
enhance growth rate by altering cell cycle kinetics and increasing the
number of cells in G1 (67% vs 57%) while decreasing the number of
cells in the G2/M phase (18% vs 27%) [72]. Gubin et al. also used an
orthotopic xenograft mouse model and demonstrated that
HuR overexpression results in significantly reduced tumor growth
and mass by 90%, as confirmed by magnetic resonance imaging
scans, gross photographs, and microscopy. Both tumors were
classified as moderately to poorly differentiated carcinoma, but
HuR-overexpressing tumors appeared to be gelatin-like capsules with
a smooth, homogeneous, and glistening surface, whereas the control
tumors were a solid round mass and had a heterogeneous,
yellow-white surface with a necrotic center [72].
In addition, HuR knockdown reduces invasiveness of MDA-
MB-231 but not MCF7 cells, as shown by a Matrigel invasion assay
[57]. In confirmation, siRNA-mediated HuR silencing was shown todecrease the invasion ability of MDA-MB-231 cells 1.4-fold, whereas
HuR overexpression increases their invasion ability two-fold. Similar
results were noted in BT-20 cells [73]. More recently,
siRNA-mediated HuR silencing was also shown to reduce invasive-
ness of MDA-MB-231 cells by 72% [49].
Moreover, siRNA-mediated HuR silencing decreases the motility
of BT-20 cells 1.6-fold, whereas HuR overexpression increases their
motility 2.4-fold [73]. In contrast, HuR knockdown does not affect
cell adhesion or migration in both MCF7 and MDA-MB-231 cells
[57], and HuR overexpression does not appear to affect apoptosis in
MDA-MB-231 cells or in an orthotopic xenograft mouse model [72].
HuR Target Genes
HuR exerts its effects on cell proliferation, invasion ability, and
motility of mammary cell lines by regulating the expression of target
genes (Table 2).
Two major types of studies have been conducted to elucidate the
global profile of HuR target genes, using immunoprecipitation of
ribonucleoprotein complexes and microarray analysis (RIP-Chip
assay), as initially described for HuB, another member of the Hu/
ELAV family [74].
The first study assessed the HuR targets in comparison with the
targets of the heterogeneous nuclear ribonucleoprotein D0
(HNRNPD/AUF1) in MCT1-transformed compared with nontrans-
formed immortalized MCF10A cells. In total, 1676 and 2072 mRNAs
exhibited significantly altered binding to HuR or HNRNPD/AUF1,
respectively, and 712 of these mRNAs exhibited differential binding to
both proteins. Functionally, these genes are mostly associated with cell
cycle regulation, signal transduction, DNA damage response, transla-
tion regulation, and angiogenesis, as demonstrated by Gene Ontology
analysis. Using the KEGGpathway database, nine pathways were found
to be significantly enriched in these genes: (1) cell cycle, (2) cell
communication, (3) p53 signaling pathway, (4) ribosome, (5) oxidative
phosphorylation, (6) purine metabolism, (7) focal adhesion, (8)
ubiquitin-mediated proteolysis, and (9) regulation of actin cytoskeleton.
Similarly, in the BioCarta pathway database, seven pathways were
significantly enriched: (1) caspase cascade in apoptosis, (2) cyclins and
cell cycle regulation, (3) Erk1/Erk2 mitogen-activated protein kinase
(MAPK) signaling, (4) Erk and phosphatidylinositol 3-kinase are
necessary for collagen binding in corneal epithelia, (5) role of Ran in
mitotic spindle regulation, (6) phosphoinositides and their downstream
targets and HIV type I Nef (negative effector of Fas and tumor necrosis
factor [TNF]) [70]. In parallel, Mazan-Mamczarz et al. applied a similar
methodology toMCF7 cells. Overall, ca. 9000 mRNAs were bound by
HuR, and 595 of them exhibited significantly altered binding to HuR
in MCT1-transformed compared with nontransformed MCF7 cells.
Functional analysis revealed that these genes are implicated in cell cycle
arrest, apoptosis, and angiogenesis together with pathways important
for cell survival and proliferation [75]. Overall, these results support the
notion that HuR plays an important role as a regulator of key gene
expression during malignant transformation.
In the second type of study, HuR targets were compared in
MDA-MB-231 and MCF7 cells. Three hundred ninety-five and 64
annotated genes were respectively identified as HuR targets, together
with 182 genes in both cell lines. Gene Ontology analysis of the genes
differentially bound by HuR in MDA-MB-231 and MCF7 cells
revealed that they are implicated in epithelial cell differentiation,
hormone metabolism, regulation of biological processes, blood vessel
morphogenesis, anatomical structure formation, vasculature
Table 2. Effect of HuR Protein on mRNA Stability and/or Translation of Genes in Breast Cancer Cell Lines
Protein Effect Cell Line Ref.
Transcription
Estrogen receptor (ESR1) mRNA stabilization↑ MCF7 [37,76]
Transacting T-cell–specific transcription factor GATA-3 (GATA3) mRNA stabilization↑ MCF7
BT474
[71]
Forkhead box protein O1 (FOXO1) mRNA stabilization↑ MDA-MB-231 [77]
Homeobox protein Hox-A5 (HOXA5) mRNA stabilization↑ MCF7 [78]
Signal transducer and activator of transcription 3 (STAT3) Expression *↑ MCF10A † [70]
Activator protein 1 (AP1) Expression *↑ MCF10A † [70]
Proto-oncogenes c-fos (FOS) Expression *↑ MCF7 [79]
Myc proto-oncogene protein (MYC) Expression *↑ MCF7 [79]
Cell signaling
Tyrosine protein kinase Yes (YES1) Expression * (?) MDA-MB-231 [80]
Protein Wnt-5a (WNT5A) Translation↓ HB2
MCF7
[50]
Insulin growth factor 1 receptor (IGF1R) Translation↓ T47D
MCF10A
[55]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) mRNA stabilization↑ SK-BR-3 [38]
Calmodulin (CALM2) mRNA stabilization↑ MCF7 [52]
Suppressor of cytokine signaling 3 (SOCS3) Expression *↑ MCF7 [79]
C-X-C chemokine receptor type 4 (CXCR4) mRNA stabilization↑ MDA-MB-231 [81]
Cell cycle
Cyclin-dependent kinase inhibitor 1 (CDKN1A) mRNA stabilization↑ MDA-MB-468 [82]
Breast cancer type 1 susceptibility protein (BRCA1) Translation↓ MCF7, T47D [56]
G1/S-specific cyclin E1 (CCNE1) mRNA stabilization↑ MCF7
MCF10A
[53]
Cellular tumor antigen p53 (TP53) Expression *↑ MCF10A
MCF7
SK-BR-3
[60,69]
Protein phosphatase 1D (PPM1D/WIP1) Expression *↑ MCF7
SK-BR-3
[60]
Tumor protein 63-delta Np63 (TP63) Translation↓ MCF10A [69]
Cyclin-dependent kinase 1 (CDK1) Expression↑ MCF10A † [70]
Cyclin-dependent kinase 7 (CDK7) Expression↑ MCF10A † [70]
DNA repair protein RAD51 homolog 1 (RAD51) Expression↑ MCF10A † [70]
Inflammation
Interleukin-8 (CXCL8) mRNA stabilization↑ Hs578T [58]
Macrophage colony-stimulating factor 1 receptor (CSF1R) mRNA stabilization↑ BT-20
SK-BR-3
[51]
Cyclooxygenase-2 (COX2) mRNA stabilization↑ MDA-MB-231 [83]
Cell adhesion and angiogenesis
CD9 antigen (CD9) mRNA stabilization↑
mRNA stabilization↓
MCF7
MDA-MB-231
[52]
Thrombospondin-1 (THBS1) mRNA stabilization↑ MCF7 †
MDA-MB-231
[72,75]
Vascular endothelial growth factor A (VEGFA) Expression *↓
Expression *↑
MDA-MB-231
MCF7
[59,72]
Platelet-derived growth factor-C (PDGF-C) mRNA stabilization↑ MDA-MB-231 [84]
Matrix metalloproteinase-9 (MMP9) mRNA stabilization↑ MDA-MB-231 [57]
Apoptosis
Tumor necrosis factor ligand superfamily member 12 (TNFSF12) Expression *↑ MCF10A † [70]
Apoptosis regulator BAX (BAX) Expression *↑ MCF10A † [70]
Caspase-2 (CASP2) Expression *↑ MCF10A † [70]
Others
Eukaryotic translation initiation factor 4E–binding protein 2 (eIF4EBP2) Expression *↑ MCF10A † [70]
Ras-related protein Rab-2 A (RAB2A) Expression *↑ MCF10A † [70]
* The term expression signifies that the exact mechanism of regulation has not been elucidated.
† MCT-1–transformed cell line.
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regulation of metabolic processes, transcriptional regulation, regula-
tion or cellular processes, and signal transduction [52].
Besides these high-throughput studies, the physical interaction of
HuR with individual genes was demonstrated by immunoprecipita-
tion. Additionally, immunoblotting, northern hybridization, quanti-
tative polymerase chain reaction amplification, or luciferase reporter
genes were all regularly used in transcription and cell signaling assays
to elucidate the regulatory mechanism of gene expression.Transcription
ER is the major mediator of the mitogenic effects of estrogen in the
mammary gland [85]. HuR binds to the 3′-UTR of ER mRNA in
MCF7 cells [37], and siRNA-mediated HuR silencing resulted to a
downregulation of ER mRNA levels and half-life [76]. Notably, HuR
phosphorylation increases its binding to the 3′-UTR of the ER
mRNA; more specifically, phosphorylation at the S88, S100, and
T118 sites is necessary for HuR binding to the ER 3′-UTR, as
demonstrated by the use of HuR phosphorylation mutants [37].
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implicated in cell differentiation, whereas its expression has been
correlated with ER expression in breast cancer [86]. HuR binds to the
3′-UTR of GATA-3 mRNA in MCF7 cells, whereas siRNA-
mediated HuR silencing decreased GATA-3 mRNA and protein
levels in MCF7 and BT474 cells, respectively. In addition, the
half-life of GATA-3 mRNA was significantly reduced. Interestingly,
siRNA-mediated silencing of either HuR or GATA-3 inhibited cell
proliferation by 35% and 44%, respectively [71].
Forkhead box protein O1 (FOXO1) is a transcription factor
implicated in response to oxidative stress, and HuR binds to the
3′-UTR of FOXO1 mRNA in MDA-MB-231 cells, stabilizing it and
enhancing its half-life. SiRNA-mediated HuR silencing and HuR
overexpression revealed that HuR significantly increases in FOXO1
mRNA and protein levels [77].
The homeobox protein Hox-A5 has been shown to negatively
regulate angiogenesis in breast cancer [87], and HuR binds to the
3′-UTR of the Hox-A5 mRNA in MCF7 cells. Retinoic acid
treatment (100 μM) enhances the HuR–Hox-A5 mRNA interaction
and subsequently increases Hox-A5 mRNA and protein levels.
Induction of Hox-A5 following RA treatment is co-regulated by HuR
and miR-130a, and HuR-mediated Hox-A5 regulation plays an
important role in RA-induced cell death [78].
HuR also binds to the signal transducer and activator of
transcription 3 and activator protein 1 mRNAs in MCF10A cells
[70] and to proto-oncogenes c-fos and c-myc mRNA in MCF7
cells [68].
Cell Signaling
The nonreceptor tyrosine-protein kinase Yes belongs to the SRC
subfamily and has been associated with invasion and metastasis of
breast cancer cells. HuR binds to the proximal 3′-UTR (nt
1840-3174) of the Yes mRNA in MB-MDA-231 cells and appears
to play a role in Yes expression regulation [80].
Protein Wnt-5a is a ligand for members of the frizzled family of
seven transmembrane receptors and may either activate or inhibit
canonical Wnt signaling, depending on receptor context. In breast
cancer, Wnt-5a plays a role in cell migration and invasiveness, and
low Wnt-5a expression levels are correlated with poor prognosis in
breast cancer patients [88]. HuR binds to the AU-rich sequences in
the 3′-UTR of Wnt-5a mRNA in HB2 cells. Interestingly, HuR
binding does not affect Wnt-5a mRNA stability but suppresses
Wnt-5a translation. The phenomenon was also studied under
hypoxic conditions (1% O2, 24 hours), which increased HuR
protein levels. As expected, Wnt-5a mRNA levels remained stable
during hypoxia. However, Wnt-5a protein levels were significantly
reduced, and similar results were obtained in MCF7 cells [50].
Insulin-like growth factor 1 receptor (IGF1R) is a receptor tyrosine
kinase which mediates actions of insulin-like growth factor 1,
controlling cell proliferation. HuR binds to the IRES located in the
5′-UTR of the IGF-1R mRNA in T47D and MCF10A cells.
SiRNA-mediated HuR silencing and HuR overexpression revealed
that HuR represses IGF1R IRES activity. Interestingly, HuR
competes with the heterogeneous nuclear ribonucleoprotein C
(hnRNP C) for binding to the IGF1R 5′-UTR, and the two proteins
exert opposite effects on IGF-1R IRES activity. Amino acid
deprivation (16 hours) of T47D cells downregulates HuR protein
levels but increases HuR binding to IGF-1R IRES and reduces
IRES activity, whereas induced G2/M cell cycle arrest (nocodazole,100 ng/ml, 24 hours) upregulates HuR protein levels but reduces
HuR binding and increases IRES activity [55].
Receptor tyrosine-protein kinase erbB-2, alternatively known as
tyrosine kinase-type cell surface receptor HER2 or proto-oncogene
Neu, is a protein tyrosine kinase. HuR binds to the U-rich sequence
(nt 465-505) in the 3′-UTR of the erbB2 mRNA in SK-BR-3 cells.
SiRNA-mediated HuR silencing results in a decrease of erbB2 mRNA
and protein levels [38].
Calmodulin is a regulatory protein that has been shown to interact
with ER, probably exerting an inhibitory effect [89]. HuR binds to
the 3′-UTR of the calmodulin mRNA. SiRNA-mediated HuR
silencing and HuR overexpression revealed that HuR increases
CALM2 mRNA and protein levels in MCF7 cells [52].
Suppressor of cytokine signaling 3 (SOCS3) is involved in negative
regulation of cytokines and HuR binds to the (SOCS3) mRNA in
MCF7 cells [79].
C-X-C chemokine receptor type 4 (CXCR-4) is a G-protein–
coupled chemokine receptor overexpressed in breast cancer and is
involved in metastasis, invasion, and migration of breast cancer cells.
HuR binds to the 3′-UTR of CXCR-4 mRNA in MDA-MB-231
cells. SiRNA-mediated HuR silencing resulted in a 50% reduction of
CXCR-4 mRNA and protein levels. Both HuR and CXCR-4
expression levels were low in normal tissues and higher in invasive
ductal and lobular breast carcinoma ones. Similar results were noted
in MCF10A, MCF12A, MCF7, and MDA-MB-231 cells, with the
MDA-MB-231 cells expressing 2-fold higher CXCR-4 mRNA levels
in comparison with MCF7 cells and more than a 40-fold and a
130-fold higher CXCR-4 mRNA levels as compared with the normal
MCF10A and MCF12A cells, respectively. CXCR4 protein levels are
also higher in MDA-MB-231 cells as compared with MCF10A.
Moreover, CXCR-4 mRNA was more stable in MDA-MB-231 cells
as compared with MCF10A cells. SiRNA-mediated silencing of both
CXCR-4 and HuR has significant inhibitory effects on invasion and
migration of MDA-MB-231 cells [81].
Tribbles-homolog 3 (TRB3) is a kinase-like protein implicated in
stress response. SiRNA-mediated silencing of HuR in MCF7 cells
under anoxic conditions (48 hours) reduced TRB3 mRNA by
2.4-fold and its half-life by 51% with a concomitant decrease in
TRB3 protein levels [90].
Cell Cycle
Cyclin-dependent kinase inhibitor 1 (p21) plays an important role
in cell cycle progression and acts as an inhibitor of cellular
proliferation in response to DNA damage. HuR interacts with the
3′-UTR of the p21 mRNA in MB-MDA-468 cells. More specifically,
HuR binds to the AU-rich WAF1-HuD sequence (nt 657-698)
within the WAF1-1/6 region (nt 571-829) of the p21 mRNA. HuR
binding was reported to increase after exposure of the cells to
short-wavelength ultraviolet light (254 nm, 20 J/m2, 6 hours), a
mediator of p21 mRNA stability [91], and, under the same
conditions, an approximately 70% upregulation of p21 mRNA
stability [82]. In addition, HuR knockdown decreases p21 protein
levels in MCF10A cells [69]. This constitutes a posttranscriptional
mechanism of regulation of p21 expression levels in contrast to its
transcriptional regulation by p53.
Breast cancer type 1 susceptibility protein (BRCA1) plays a central
role in DNA repair by facilitating cellular responses to DNA damage.
Notably, BRCA1 gene mutations comprise the most important
genetic susceptibility factor for breast cancer. HuR binds to the
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cells. Further experiments in HeLa cells indicate that HuR negatively
regulates BRCA1 protein levels, with no effect on mRNA levels or
stability [56].
G1/S-specific cyclin E1 plays a crucial role in the regulation of cell
cycle progression and cell proliferation. Full-length cyclin E1 together
with its functional, hyperactive, low–molecular weight isoforms is
overexpressed in breast cancer, and HuR binds to the 3′-UTR of
cyclin E1 mRNA in both MCF7 and MCF10A cells.
SiRNA-mediated HuR silencing in MCF7 cells significantly
decreased the half-life of cyclin E1 mRNA, and concomitantly,
full-length cyclin E1 protein levels were reduced by 22% and the
low–molecular weight isoforms by 80%. As a result, G1/S cell cycle
arrest was noted using flow cytometry, and cell cycle progression and
cell proliferation were subsequently restored by overexpression of the
low–molecular weight cyclin E1 isoforms. Similarly, HuR overex-
pression in MCF10A cells both increased cyclin E1 mRNA half-life
and doubled protein levels [53]. Cold-inducible RNA-binding
protein (CIRBP), which is negatively regulated by HuR while
positively affecting HuR protein levels, also increases HuR binding to
cyclin E1 mRNA, enhancing its stability [92]. Additionally, a recent
study demonstrated that miR-16 blocks HuR-mediated upregulation
of cyclin E1 in MCF7 cells [93].
The cellular tumor antigen p53 acts as a tumor suppressor by
inducing growth arrest or apoptosis. HuR binds to p53 mRNA in
MCF7 and SK-BR-3 cells, enhancing its expression [60]. In addition,
HuR knockdown decreases p53 protein levels in MCF10A cells [69].
Interestingly, cytoplasmic HuR expression pattern has been signif-
icantly associated with positive p53 immunostaining in familial
non-BRCA1/2 patients [94].
Protein phosphatase 1D (PPM1D/WIP1) is implicated in
p53-dependent checkpoint-mediated cell cycle arrest, and HuR
binds to PPM1D/WIP1 mRNA in MCF7 and SK-BR-3 cells,
enhancing its expression [60].
Isoforms of tumor protein 63, designated as delta Np63, are
known to suppress cell proliferation. HuR binds to U-rich elements
(nt 4010-4220 and nt 4640-4868) in the 3′-UTR of the delta Np63
mRNA in MCF10A cells. HuR knockdown has little effect of delta
Np63 mRNA levels but increases protein levels of delta Np63p and
its target, growth arrest and DNA damage-inducible protein
GADD45 alpha. Delta Np63 knockdown revealed that delta Np63
partly mediates HuR knockdown–induced growth suppression and
premature senescence in MCF10A cells [69].
Moreover, HuR modulates the expression of other gene products
implicated in cell cycle regulation and DNA damage response. More
specifically, HuR binds the cyclin-dependent kinase 1 (CDK1),
cyclin-dependent kinase 7 (CDK7), and DNA repair protein RAD51
homolog 1 (RAD51) mRNAs in MCF10A cells. SiRNA-mediated
HuR silencing reduced protein levels of all the above genes [70].
Finally, HuR knockdown correlates with downregulated G1/
S-specific cyclin-D1 mRNA and protein levels in MCF7 but not
MDA-MB-231 cells [57].
Inflammation
Interleukin (IL)-8 is a chemokine that promotes malignant
phenotype and metastasis in breast cancer, while being produced by
tumor cells as a response to other inflammatory cytokines in the
tumor microenvironment [95]. In addition, IL-8 is a strong inducer
of angiogenesis, and it mediates endothelial cell chemotaxis andproliferation in vitro and angiogenic activity in vivo [96]. HuR
binds to the proximal 3′-UTR of IL8 mRNA in in IL1-beta–
stimulated Hs578T cells. Stimulation with IL1-beta (5 ng/ml,
6-24 hours) also resulted in a time-dependent induction of IL-8
mRNA and protein levels and stabilization of IL-8 mRNA. Taken
together, these observations suggest that HuR contributes to IL-8
mRNA stabilization [58].
Macrophage colony-stimulating factor 1 receptor (CSF-1-R),
alternatively known as proto-oncogene c-fms, is associated with cell
proliferation, metastasis, and poor survival [97]. A statistically
significant association between high nuclear and cytoplasmic HuR
and high cytoplasmic CSF-1-R expression levels has been observed.
HuR binds to a 69-nt element which contains 5 “CUU” motifs
within the 3′-UTR of CSF-1-R mRNA in BT-20 and SK-BR-3 cells.
Site-directed mutagenesis confirmed the necessity of these motifs for
binding [51]. Interestingly, vigilin, a regulator of lipid metabolism,
also binds to the same 69-nt element competing with HuR and
exerting negative effects on CSF-1-R mRNA and protein levels [73].
SiRNA-mediated HuR silencing and HuR overexpression revealed
that HuR increases CSF-1-R RNA and protein levels in both BT-20
and SK-BR-3 cells, respectively. In addition, glucocorticoid stimu-
lation of CSF-1-R expression is largely dependent on the presence of
HuR [51].
Cyclooxygenase (COX)-2, also known as prostaglandin G/H
synthase 2 (PTGS2), is responsible for the production of inflamma-
tory prostaglandins. HuR binds to COX-2 mRNA in MDA-MB-231
cells. As a result, COX-2 mRNA is stabilized [83]. Interestingly,
increased HuR protein levels were significantly associated with
increased COX-2 expression in DIC patients [66].
Cell Adhesion and Angiogenesis
CD9 antigen is implicated in cell adhesion and cell motility,
together with tumor metastasis. HuR binds to the 3′-UTR of the
CD9 mRNA and differentially regulates its mRNA and protein levels
in MDA-MB-231 and MCF7 cells. More specifically,
siRNA-mediated HuR silencing and HuR overexpression revealed
that HuR decreases CD9 mRNA and protein levels in
MDA-MB-231 cells while increasing CD9 mRNA and protein levels
in MCF7 cells [52].
The angiogenesis inhibitor thrombospondin-1 (THBS1) is a
glycoprotein functioning as a tumor suppressor [98]. THBS1 plasma
levels have been positively correlated with breast cancer progression
[99]. HuR binds to the terminal the 3′-UTR of THBS1 mRNA in
MCF10A and MDA-MB-231 cells [72,75]. SiRNA-mediated HuR
silencing and HuR overexpression revealed that HuR modulates
THBS1 protein levels. More specifically, a two-fold decrease or
increase of THBS1 protein levels was noted in HuR-silenced and
HuR-overexpressing MCF7 cells, respectively. Interestingly, the
association between HuR and THBS1 mRNA was reduced by
65% to 85% in MCT1-transformed MCF7 cells [75].
HuR-overexpressing tumors in an orthotopic xenograft mouse
model exhibited increased THBS1 mRNA (5.44-fold) and protein
(76%) levels [72].
Vascular endothelial growth factor A (VEGF-A) is a growth
factor involved in angiogenesis. HuR was shown to bind to
VEGF-A mRNA in MDA-MB-231 cells. Surprisingly, HuR-
overexpressing tumors in orthotopic mice exhibited decreased
VEGF-A mRNA (2.6-fold) and protein (23%) levels with no
alteration in stability [72].
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in cell proliferation and migration, and its expression has been
associated with poor prognosis in breast cancer patients. HuR and
PDGF-C expression levels have been correlated in mammary cell lines
and breast cancer patients, and direct binding of HuR to the 3′-UTR
of the PDGF-C mRNA has been demonstrated. SiRNA-mediated
HuR silencing confirmed the stabilization of PDGF-C mRNA by
HuR in MDA-MB-231 cells. HuR-mediated upregulation of
PDGF-C appears to be involved in the responses against ultraviolet
irradiation (30 J/m2) and oxidative stress (H2O2, 800 μM, 24 hours)
in MCF7 cells [84].
Matrix metalloproteinase (MMP)-9 plays an essential role in local
proteolysis of extracellular matrix and cell migration. MMP-9 is
overexpressed in breast cancer and has been associated with metastasis
[100]. HuR knockdown correlates with reduced MMP-9 mRNA and
protein levels in MDA-MB-231 but not in MCF7 cells [57].
Hypoxia-induced factor 1 alpha (HIF-1-alpha) is the main
transcriptional regulator in response to hypoxic conditions, facilitating
metabolic adaptation to hypoxia and playing a crucial role in tumor
angiogenesis, with increased HIF-1-alpha expression levels associated
with poor patient survival [101]. SiRNA-mediated silencing of HuR
reduced HIF-1-alpha protein levels in MCF7 and Hs578T cells [59].
Apoptosis
HuR positively regulates the expression of gene products promoting
programmed cell death. Analytically, HuR binds the tumor necrosis
factor ligand superfamily member 12 (TNFSF12), apoptosis regulator
BAX, caspase-2 (CASP2) mRNAs in MCF10A cells. SiRNA-mediated
HuR silencing reduced protein levels of these genes [70].
Others
Finally, HuR is implicated in the expression regulation of gene
products involved in translation, such as the eukaryotic translation
initiation factor 4E–binding protein 2 (eIF4EBP2) and the CIRBP, and
in protein transport from the endoplasmic reticulum to the Golgi
complex, namely, the Ras-related protein Rab-2A (RAB2A). More
specifically, HuR binds the eIF4EBP2 and RAB2A mRNAs in
MCF10A cells, and siRNA-mediated HuR silencing reduced protein
levels of these genes [70]. SiRNA-mediated HuR silencing increases
both CIRBPmRNA and protein levels by two-fold inMCF7 cells [92].
HuR Modulators
A number of environmental conditions, proteins, microRNAs, and
drugs have been shown to directly or indirectly modulate HuR
expression and activity in mammary cell lines (Table 3).
Ultraviolet irradiation upregulates HuR protein levels in MCF7
cells in a dose-dependent manner [84]. Furthermore, anoxia (b0.01%
O2) increases cytoplasmic HuR expression levels in MCF7 cells. More
specifically, a significant translocation of the nuclear HuR to the
cytoplasm after 12 hours of anoxic incubation, and translocation of
majority of HuR to the cytoplasm after 24 hours was noted [90]. In
addition, oxidative stress (H2O2, 800 μM, 24 hours) and induced
G2/M cell cycle arrest (nocodazole, 100 ng/ml, 24 hours) upregulate
HuR protein levels, whereas amino acid deprivation (16 hours)
downregulates HuR protein levels [55,84].
Proteins Modulating HuR Expression
BRCA1-IRIS is a product of the BRCA1 locus, the expression of
which is associated with breast cancer aggressiveness [103].SiRNA-mediated BRCA1-IRIS silencing and BRCA1-IRIS overex-
pression revealed that BRCA1-IRIS increases total and cytoplasmic,
but not nuclear, HuR expression levels in MCF7 and SK-BR-3 cells.
The exact mechanism was not elucidated, but it probably involves
nuclear factor–kappaB [60], which is known to activate HuR
transcription [104]. Moreover, BRCA1-IRIS was shown to increase
HuR binding to p53 and PPM1D, enhancing their expression [60].
CIRBP is a stress response translation activator, overexpressed in
breast cancer [105], which may promote cell immortalization.
SiRNA-mediated CIRBP silencing and CIRBP overexpression
revealed that CIRBP positively regulates HuR protein levels and
increases HuR-containing cytoplasmic stress granules in MCF7 cells.
However, CIRBP induces no changes to HuR mRNA levels or
nuclear-to-cytoplasmic ratio [92].
Heat-shock factor protein 1 (HSF-1) is a transcription factor
known to be involved in breast cancer progression and metastasis
[106]. SiRNA-mediated HSF-1 silencing downregulates HuR
mRNA and protein levels in MCF7 and Hs578T cells. A reduction
of HuR mRNA and protein levels was also noted in a HSF-1
knockdown MCF7 xenograft mouse model. Because HuR mRNA
stability is not affected, HSF-1 probably modulates HuR at the level
of transcription. In addition, HSF-1 knockdown results in
downregulation of a number of known HuR targets in MCF7 and
Hs578T cells, such as HIF-1-alpha, HIF-2-alpha, also known as
endothelial PAS domain-containing protein 1 (EPAS-1), VEGF-A,
p53, G2/mitotic-specific cyclin-B1, and NAD-dependent protein
deacetylase sirtuin-1 (SIRT1), and represses tumor growth and
angiogenesis in vivo [59].
Tristetraproline (TTP), similar to HuR, is an RNA-binding
protein that posttranscriptionally regulates gene expression. TTP
binds HuR mRNA in MDA-MB-231 cells, negatively regulating
HuR mRNA levels. TTP itself is negatively modulated by miR-29a,
which binds to the 3′-UTR of TTP mRNA. An abnormally low
TTP:HuR ratio is noted in invasive ductal and lobular carcinomas as
compared with normal breast tissue. The low TTP:HuR ratio,
together with enhanced miR-29a expression, is also evident in
MDA-MB-231 cells in comparison with MCF10A, MCF12A, and
MCF7 cells. MiR-29a expression in MCF10A cells increases HuR
mRNA levels 5-fold while reducing TTP mRNA levels by 40%,
resulting in the abnormally low TTP:HuR ratio. Conversely,
miR-29a inhibition in MDA-MB-231 cells decreases HuR mRNA
levels by 4-fold, while enhancing TTP mRNA levels 2-fold. It also
downregulates HuR targets urokinase-type plasminogen activator,
MMP-1 (also known as interstitial collagenase), and MMP-13 (also
known as collagenase 3) at both the mRNA and protein level and
reduces cell invasiveness by 64% [49].
MicroRNAs Modulating HuR Expression
MiR-125 binds to the 3′-UTR (nt 686-692) of HuR mRNA and
represses its translation, and an inverse correlation was observed
between HuR protein level and miR-125 expression levels in
MCF10A, MCF7, T47D, SK-BR-3, and HMT-3522-T4-2 cells.
MCF10A cells have lower HuR protein levels and higher miR-125
levels than the other cell lines, whereas high levels of both HuR and
miR-125 were noted in MDA-MB-231 cells. MiR-125a and b reduce
HuR protein levels in MCF7 and T47D cells, miR-125a slightly
decreases HuR protein levels in MCF10A cells, whereas neither
miR-125a nor miR-125b affects HuR protein levels in
MDA-MB-231 cells. Further studies revealed that, in MCF7 cells,
Table 3. Effect of HuR Modulators on HuR Expression and Function in Breast Cancer Cell Lines
Regulators Effect on HuR Cell Line Ref.
Environmental conditions
G2/M cell cycle arrest HuR protein levels↑ T47D [55]
Amino acid deprivation HuR protein levels↓ T47D [55]
Anoxia (b0.01% O2) HuR shuttling↑ MCF7 [90]
Ultraviolet irradiation HuR protein levels↑ MCF7 [84]
Oxidative stress HuR protein levels↑ MCF7 [84]
Proteins
Breast cancer type 1 susceptibility protein (BRCA1)-IRIS HuR transcription↑
MCF7
SK-BR-3
[60]
Mitogen-activated protein kinase 8 (MAPK8) HuR shuttling↑
MCF7
MDA-MB-231
ΒΤ474
[37,102]
Cold-inducible RNA-binding protein (CIRBP) HuR protein levels↑ MCF7 [92]
Heat-shock factor protein 1 (HSF1) HuR transcription↑
MCF7
Hs578T
[59]
Protein kinase C (PKC) delta HuR shuttling↑ MCF7 [61,79]
Tristetraproline (TTP) HuR mRNA levels↓
MCF10A
MCF12A
MCF7
MDA-MB-231
[49]
Εpidermal growth factor receptor (EGFR) HuR binding↑ MDA-MB-231 [83]
microRNAs
miRNA-125 HuR translation↓
MCF10A
MCF7
T47D
[54]
miRNA-16 HuR translation↓ MDA-MB-231 [63]
miRNA-29a HuR mRNA levels↑
MCF10A
MDA-MB-231
[49]
miRNA-7 HuR binding↓ MDA-MB-231 [83]
Drugs
Trichostatin A (TSA, 100 ng/ml) HuR shuttling↓
MCF7
MDA-MB-231
[37,76,102]
5-aza-2′-deoxycytidine (AZA, 2.5 μμ) HuR shuttling↓
MCF7
MDA-MB-231
[37,76,102]
Tamoxifen (2.5 μμ) HuR shuttling↑
MCF7
MDA-MB-231
ΒΤ474
[37,102]
Doxorubicin (10 μμ) HuR shuttling↑ MCF7 [61,79]
5-Fluorouracil (5-FU) HuR mRNA↑ MDA-MB-231 [77]
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together with cell proliferation by 72% and migration by 62%, in an
HuR-dependent manner [54].
MiR-16 was predicted to bind to the 3′-UTR (nt 1881-1901) of
HuR mRNA in MDA-MB-231 cells, downregulating HuR protein
but not mRNA levels. As a result, the mRNA levels of HuR target
genes, such as COX-2, SIRT1 and c-fos, were also affected.
Seventy-seven percent (10 out of 13) of samples derived from
invasive ductal breast carcinoma patients exhibited 1.5- and 8.5-fold
increases of HuR mRNA and protein levels, respectively in tumor
tissues when compared with normal tissues. In contrast, a 37%
decrease of miR-16 levels in tumor tissues was noted [63].
Drugs Modulating HuR Expression and Function
Tamoxifen is a drug that targets ER signaling and is widely used
in breast cancer treatment. Trichostatin A (TSA) and 5-aza-
2′-deoxycytidine (AZA) are inhibitors of histone deacetylation and
DNA methylation, respectively. They are used to restore ER
expression in ER-negative mammary tumors, sensitizing them to
tamoxifen treatment. Surprisingly, they have the opposite effect on
ER-positive cell lines, reducing ER expression levels [107]. Treatment
with AZA (2.5 μM, 96 hours) and TSA (100 ng/ml, 16 hours)
represses MAPK8 phosphorylation and activity, resulting in increased
nuclear-to-cytoplasmic HuR expression ratio and decreased ER
protein expression in MCF7 cells. Reduced cytoplasmic HuRexpression levels were also noted in MDA-MB-231 cells, whereas
total HuR protein levels appear slightly downregulated in MCF7 but
not in MDA-MB-231 cells [37,76]. In contrast, tamoxifen treatment
(2.5 μM) activates MAPK8, increasing cytoplasmic HuR expression
levels in MCF7 and MDA-MB-231 cells [37,102]. Inhibition of
MAPK8 in tamoxifen-sensitive MCF7 cells and tamoxifen-resistant
BT474 cells resulted in reduced proliferation and increased sensitivity
to tamoxifen. SiRNA-mediated HuR silencing in both MCF7
and BT474 cells and HuR overexpression in MCF7 cells revealed
that HuR plays a role in tamoxifen resistance [37]. Finally,
MDA-MB-231 cells were treated simultaneously with AZA, TSA,
and tamoxifen. When tamoxifen is added together with TSA,
cytoplasmic HuR expression levels are increased, but when they are
administered separately, cytoplasmic HuR expression levels are
reduced [102].
Doxorubicin is a widely used chemotherapeutic agent. Doxorubi-
cin treatment (10 μM) induces HuR phosphorylation and
subsequent nucleocytoplasmic shuttling in MCF7 cells and promotes
HuR binding to its targets, such as c-fos, c-myc, and SOCS3 [79].
More specifically, doxorubicin activates protein kinase C delta,
which phosphorylates HuR on serines 221 and 318 [46,61]. In
contrast, HuR protein levels are reduced in doxorubicin-resistant
MCF7 and MBA-MD-231 cells, and HuR cellular localization is not
affected by doxorubicin treatment in MCF7 doxorubicin-resistant
cells [79]. SiRNA-mediated HuR silencing and inhibition of HuR
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induced apoptosis is HuR dependent [79].
Lapatinib (GW-572,016), an oral dual tyrosine kinase inhibitor of
the epidermal growth factor receptor (EGFR) and human epidermal
growth factor receptor 2 (HER2), has proved effective for the
treatment of advanced HER2-positive breast cancer patients. In
contrast, lapatinib treatment of triple-negative EGFR-overexpressing
breast cancer patients enhances migration and invasion, resulting in a
worse clinical outcome [108]. A series of experiments using
siRNA-mediated gene silencing revealed that lapatinib treatment
(1 μM) of MDA-MB-231 cells downregulates miR-7, resulting in
upregulation of EGFR mRNA and protein levels. Subsequently,
EGFR interacts with HuR and enhances HuR binding to COX-2
mRNA, which is then stabilized. Finally, upregulated COX-2
expression levels lead to increased migration and invasion of
MDA-MB-231 cells in vitro and in orthotopic mice [83].
5-Fluorouracil (5-FU) is a pyrimidine analogue used as anticancer
therapeutic agent. 5-FU increases HuR mRNA and protein levels in
MDA-MB-231 cells in a dose-dependent manner. Similarly, HuR
target FOXO1 expression levels are also upregulated and
HuR-mediated modulation of FOXO1 plays a critical role in
5-FU–induced apoptosis [77].Table 4. Clinical Significance of HuR Expression in Breast Cancer Patients
Type of
Neoplasia
Patient
Samples
HuR Localization HuR Asso
Nuclear Cytoplasmic Total
ADH 71 35/71
(47%)
DCIS 74 35/74
(49%)
DIC 82 63/82
(77%)
38/82
(46%)
13 ↓ miR-16
97 ↑ tumor g
HER2(−)
89 ↑ bioener
↑ survival
133 132/133
(100%)
53/133
(40%)
208 128/208
(61%)
63/208
(30%)
623 268/623
(43%)
143 ↑ survival
IC + NACT 139 60/139
(42%)
Abbreviation: IC, invasive carcinoma.
* In familial non-BRCA1/2 cases.
† Overall survival.
‡ Disease-free survival.
§ Progression-free survival.Clinical Significance of HuR Expression
Clinical studies in DIC patients revealed a statistically significant
association between elevated total HuR expression and advanced
tumor histological grade and HER2-negative status [56]. Further-
more, nuclear HuR expression pattern was positively associated with
histological grade in invasive breast carcinoma patients [66], whereas
cytoplasmic HuR expression pattern was correlated with advanced
patients' age and tumor histological grade in carcinoma cases [65],
with increased tumor grade in DCIS [64] and in invasive breast
carcinomas [66,68], and with increased histological grade and ductal
tumor type in familial non-BRCA1/2 cases [94] and in invasive
carcinoma patients receiving NACT [64]. Moreover, it correlated
with PR-negative status in DCIS [64], in familial non-BRCA1/2 cases
[94], and in invasive carcinoma patients receiving NACT [68] and
with ER-negative status in familial non-BRCA1/2 cases [94] and in
invasive carcinoma patients receiving NACT [68]. In contrast,
cytoplasmic HuR expression pattern was associated with PR-, ER-
and HER2-positive status [65]. With reference to the role of HuR as a
prognosticator in breast cancer patients, low total HuR expression was
identified as an independent prognostic factor for reduced survival
rate in DIC patients [57,62]. Additionally, high cytoplasmic HuR
immunopositivity is an independent prognosticator for reducedciations & Prognostic Value Ref.
Nuclear Cytoplasmic
[64]
↑ tumor grade
↑ aggressiveness
PR(−)
[64]
↑MDR1
↑ age
↑ histological grade
PR(+)
ER(+)
HER2(+)
↓ survival†,‡
[65]
[63]
rade [56]
getic phenotype
‡,§
[62]
↓ survival†,‡ [67]
↑ histological grade
↑ COX-1
↑ COX-2
↑ COX-2 [66]
↑ histological grade *
↑ ductal tumor type *
PR(−) *
ER(−) *
↑ p53
↓ survival*
,†
[94]
‡,§ [57]
↑ DIC
↑ tumor grade
↑ histological grade
PR(−)
ER(−)
↓ survival†,‡
[68]
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receiving NACT [68], and familial non-BRCA1/2 patients [94]
(Table 4).
Conclusion
In total, HuR has been confirmed to bind to 38 protein-coding
mRNAs in mammary cell lines, summarized in Table 2, modulating
their expression posttranscriptionally. In the majority of the cases and
as anticipated, HuR stabilizes the target mRNA. Surprisingly though,
CD9 antigen mRNA levels were downregulated in MDA-MB-231
HuR-overexpressing cells and upregulated following siRNA-mediated
HuR silencing [52], indicating that HuR may also exert aFigure 2. Schematic representation of the regulatory axes mediated b
of the cartoon. All shapes above the rectangle are proteins, miRNAs, d
function. All shapes below the rectangle are genes regulated by HuR. B
negative regulation; dotted lines signify the lack of known direct bi
colored arrows point to biological processes experimentally proven tdestabilizing effect. HuR is also known to affect translation,
suppressing Wnt-5a [50], delta Np63 [69], IGF-1-R [55], and
BRCA1 [56] protein production. There are also a number of genes
modulated by HuR for which the regulatory mechanism has not been
elucidated, at least in mammary cell lines. Some of them have been
studied extensively in other systems; for example, HuR is known to
enhance p53 translation in colorectal carcinoma cells [75]. In
addition, HuR is responsible for the expression regulation of another
seven genes, although direct binding of HuR to the mRNAs was not
demonstrated in mammary cell lines. Again, four out of seven of these
genes, CCNB1, HIF1, HIF2, and PLAU, are known HuR targets,
modulated at the mRNA stability level [33,109–111].y HuR in breast cancer cells. HuR is the wide rectangle in the middle
rugs, and environmental conditions regulating HuR expression and
lue arrows indicate positive regulation; red horizontal lines indicate
nding of HuR on the target gene in breast cancer cells. The wide
o be affected by these regulatory axes.
normal breast cell
ER+MCF-7 cell
ER-MDA-MB-231 cell
cell proliferation 
cell proliferation
cell polarity
invasion & migration 
inflammation 
angiogenesis 
cell differentiation
HuR cytoplasm
mRNA nucleus
Figure 3. Proposed model on the localization and function of HuR
in normal mammary cells, early-stage mammary tumors (as
typified by the ER-positive MCF-7 cell line), and late-stage
mammary tumors (as typified by the ER-negative MDA-MB-231
cell line). The cytoplasmic HuR expression levels are correlated
with the degree of malignancy, and HuR binding to different
target mRNAs leads to differential regulation of cancer-related
biological processes.
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HuR in breast cancer cell lines representing various tumor progression
stages, and HuR appears to exert opposite effects on VEGF-A in
MCF7 and MDA-MB-213 cells. More specifically, HuR was
observed to upregulate VEGF-A protein levels in nonmetastatic
MCF7 cells [59], possibly by stabilizing its mRNA as reported
previously [112]. In contrast, in an in vivo mouse model xenografted
with MDA-MB-231 cells, HuR repressed VEGF-A protein levels
[72]. Another gene product differentially regulated in MCF7 and
MDA-MB-213 cells is CD9 antigen [52].
The majority of genes modulated by HuR are implicated in
biological processes such as cell proliferation, invasion, and migration,
together with angiogenesis and tumor growth. Additionally, the link
between HuR and these processes has been demonstrated directly in
some of the studies reported here, verifying the importance of HuR
expression and function in breast cancer progression (Figure 2).
Interestingly, HuR promotes growth in the nontumorigenic
MCF10A cells and in the ER-positive MCF7 cells, as illustrated
both by direct proliferation assays [57,69,71] and by the regulation of
genes involved in cell cycle (Table 2). In contrast, HuR has little effect
on the growth of the ER-negative, highly tumorigenic MDA-MB-231
cells; however, it appears to be at least partly responsible for their
invasive phenotype [49,73]. Regarding apoptosis, HuR upregulates
proapoptotic genes in MCT-1–transformed MCF10A cells (Table 2)
but has no effect on MDA-MB-213 cells [72]. Figure 3 summarizes
the HuR-mediated differential regulation of important biological
processes in different cell lines.
Moreover, a number of clinical studies in breast cancer patients
demonstrate that HuR is significantly correlated with advanced
clinicopathological parameters, indicating that high HuR expression
levels may constitute an aggravating factor for tumor growth and
metastasis. Furthermore, a cytoplasmic HuR expression pattern
appears to be an independent prognostic factor for reduced breast
cancer patients' survival. This observation is in agreement with
clinical studies in other cancer types [34].
Because HuR appears to be a common denominator and regulator
for a number of pathways crucial for tumor formation, growth, and
metastasis; is implicated in chemoresistance mechanisms to thera-
peutic drugs, such as tamoxifen; and is associated with important
potential therapeutic targets, such as cyclin D1 [113], CDK1 [114],
CDK7 [115], MPP-13 [116], and YES1 [117], it is feasible that HuR
itself could constitute a possible drug target for cancer therapy.
Targeting HuR would likely mitigate the severity of the disease and
delay progression, and because HuR is implicated in multiple
cancer-related pathways, it should be possible to simultaneously block
at least a few if not all of them using therapeutic agents that act via
HuR. Interestingly, HuR is implicated in retinoic acid-, doxorubicin-,
and 5-FU–mediated apoptosis [77–79], suggesting another possible
mode of action for the prospective therapeutic drugs. Future studies
should be focused to the discovery and development of HuR-specific
drugs for treatment of breast cancer and possibly other cancer types.
Recently a number of high-throughput screening methods have been
established to identify low–molecular weight agents against HuR,
including a confocal fluctuation spectroscopic assay [118], fluores-
cence polarization assays [119,120] coupled with nuclear magnetic
resonance [120], and a mammalian cell based system [121]. As a
result, a number of promising chemicals binding to HuR and
disrupting HuR dimerization and HuR-mRNA interactions have
been reported, such as MS-444, dehydromutactin, okicenone [118],quercetin, b-40, and b-41 [122], mitoxanthrone [121], CMLD-2
[119], and 15,16-dihydrotanshinone [123]. The latter, a traditional
Chinese medicine, is of particular interest because it has been assessed
in breast cancer cell lines and was shown to have HuR-dependent
antiproliferative (1 mM) and cytotoxic (10 mM) effects in MCF-7
cells and to inhibit the migration of MDA-MB-231 cells [123].
Additionally, 15,16-dihydrotanshinone [123] and dehydromutactin
[118] were noted to affect the subcellular localization of HuR, leading
to increased nuclear-to-cytoplasmic HuR ratio. Similarly,
apoptosis-inducing CMLD-2 was demonstrated to be preferentially
cytotoxic against (colon and pancreatic) cancer cells when compared
with normal cells and to suppress the oncogenic Wnt signaling [119].
All the above effects are mediated by the resulting alterations to
mRNA stability and translation of various HuR target genes. Two
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already known for their properties against cancer, which are now
shown to be at least partly HuR dependent [118]. Which, if any, of
these compounds would be effective against breast cancer remains an
open question. To this end, further investigation is required to
elucidate HuR mechanisms of action and determine at which stage of
the disease and against which types of breast cancer a specific
therapeutic agent targeting HuR would be more effective. The
construction of stable mammary cell lines for inducible HuR
expression would be an initial step toward this direction prior to
in vivo animal and clinical studies.
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